Integra LifeSciences [IART] vs Boston Scientific [BSX] Detailed Stock Comparison
Integra LifeSciences
NASDAQ
Loading...
Boston Scientific
NYSE
Loading...
TLDR: Quick Comparison Summary
Based on 19 vital metrics comparison: Integra LifeSciences wins in 5 metrics, Boston Scientific wins in 14 metrics, with 0 ties. Boston Scientific appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Integra LifeSciences | Boston Scientific | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 66.48 | 61.14 | Boston Scientific |
| Price-to-Book Ratio | 1.13 | 6.78 | Integra LifeSciences |
| Debt-to-Equity Ratio | 194.07 | 53.09 | Boston Scientific |
| PEG Ratio | 5.98 | 0.42 | Boston Scientific |
| EV/EBITDA | 9.60 | 34.84 | Integra LifeSciences |
| Profit Margin (TTM) | -30.87% | 13.55% | Boston Scientific |
| Operating Margin (TTM) | 7.86% | 18.63% | Boston Scientific |
| EBITDA Margin (TTM) | 7.86% | 18.63% | Boston Scientific |
| Return on Equity | -38.92% | 11.55% | Boston Scientific |
| Return on Assets (TTM) | 2.43% | 5.39% | Boston Scientific |
| Free Cash Flow (TTM) | $15.01M | $2.37B | Boston Scientific |
| 1-Year Return | -13.80% | 23.30% | Boston Scientific |
| Price-to-Sales Ratio (TTM) | 0.72 | 8.23 | Integra LifeSciences |
| Enterprise Value | $2.94B | $163.92B | Boston Scientific |
| EV/Revenue Ratio | 1.81 | 8.86 | Integra LifeSciences |
| Gross Profit Margin (TTM) | 50.37% | 67.65% | Boston Scientific |
| Revenue per Share (TTM) | $21 | $13 | Integra LifeSciences |
| Earnings per Share (Diluted) | $-6.54 | $1.68 | Boston Scientific |
| Beta (Stock Volatility) | 1.20 | 0.66 | Boston Scientific |
Performance
News Sentiment
Key Stats
Valuation
Financials
Short Interest
Dividends
Integra LifeSciences vs Boston Scientific Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Integra LifeSciences | -2.65% | -5.82% | 9.37% | 18.68% | -32.28% | -34.58% |
| Boston Scientific | -1.56% | -4.21% | 0.07% | 4.21% | 6.52% | 14.91% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Integra LifeSciences | -13.80% | -66.94% | -67.70% | -53.11% | -22.41% | -17.25% |
| Boston Scientific | 23.30% | 146.33% | 166.94% | 513.25% | 1,795.20% | 324.46% |
News Based Sentiment: Integra LifeSciences vs Boston Scientific
Integra LifeSciences
News based Sentiment: MIXED
The month presented a mixed bag for Integra LifeSciences, with a stock price decline and negative price prediction offset by a clear growth strategy for 2026 and ongoing operational improvements. Analyst sentiment remains cautious, reflecting the ongoing challenges and uncertainties surrounding the company's turnaround.
Boston Scientific
News based Sentiment: MIXED
September brought a mix of positive and cautionary signals for Boston Scientific. While the company issued strong guidance and secured a strategic acquisition, continued insider selling and mixed institutional activity introduce uncertainty. The overall narrative suggests a company with growth potential but also potential internal concerns.
Performance & Financial Health Analysis: Integra LifeSciences vs Boston Scientific
| Metric | IART | BSX |
|---|---|---|
| Market Information | ||
| Market Cap | $1.17B | $152.19B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 1,202,480 | 7,267,900 |
| 90 Day Avg. Volume | 1,384,253 | 6,400,743 |
| Last Close | $15.06 | $102.71 |
| 52 Week Range | $11.06 - $27.13 | $80.64 - $109.50 |
| % from 52W High | -44.49% | -6.20% |
| All-Time High | $77.40 (Apr 26, 2021) | $109.50 (Sep 09, 2025) |
| % from All-Time High | -80.54% | -6.20% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.01% | 0.23% |
| Quarterly Earnings Growth | -0.01% | 1.46% |
| Financial Health | ||
| Profit Margin (TTM) | -0.31% | 0.14% |
| Operating Margin (TTM) | 0.08% | 0.19% |
| Return on Equity (TTM) | -0.39% | 0.12% |
| Debt to Equity (MRQ) | 194.07 | 53.09 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $13.33 | $15.14 |
| Cash per Share (MRQ) | $3.26 | $0.36 |
| Operating Cash Flow (TTM) | $70.89M | $4.28B |
| Levered Free Cash Flow (TTM) | $45.35M | $2.94B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | N/A |
| Last 12-Month Dividend | N/A | N/A |
Valuation & Enterprise Metrics Analysis: Integra LifeSciences vs Boston Scientific
| Metric | IART | BSX |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 66.48 | 61.14 |
| Forward P/E | 5.98 | 36.81 |
| PEG Ratio | 5.98 | 0.42 |
| Price to Sales (TTM) | 0.72 | 8.23 |
| Price to Book (MRQ) | 1.13 | 6.78 |
| Market Capitalization | ||
| Market Capitalization | $1.17B | $152.19B |
| Enterprise Value | $2.94B | $163.92B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 1.81 | 8.86 |
| Enterprise to EBITDA | 9.60 | 34.84 |
| Risk & Other Metrics | ||
| Beta | 1.20 | 0.66 |
| Book Value per Share (MRQ) | $13.33 | $15.14 |
Financial Statements Comparison: Integra LifeSciences vs Boston Scientific
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | IART | BSX |
|---|---|---|
| Revenue/Sales | $415.61M | $4.66B |
| Cost of Goods Sold | $206.27M | $1.45B |
| Gross Profit | $209.33M | $3.21B |
| Research & Development | $27.00M | $443.00M |
| Operating Income (EBIT) | $-1.31M | $937.00M |
| EBITDA | $39.15M | $1.23B |
| Pre-Tax Income | $-530.95M | $805.00M |
| Income Tax | $-46.88M | $133.00M |
| Net Income (Profit) | $-484.07M | $672.00M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | IART | BSX |
|---|---|---|
| Cash & Equivalents | $239.10M | $725.00M |
| Total Current Assets | $1.11B | $7.34B |
| Total Current Liabilities | $918.45M | $5.06B |
| Long-Term Debt | $1.39B | $10.93B |
| Total Shareholders Equity | $1.52B | $22.45B |
| Retained Earnings | $914.62M | $3.35B |
| Property, Plant & Equipment | $561.38M | $448.00M |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | IART | BSX |
|---|---|---|
| Operating Cash Flow | $5.80M | $513.00M |
| Capital Expenditures | $-28.92M | $-187.00M |
| Free Cash Flow | $-40.18M | $277.00M |
| Debt Repayment | $-15.24M | $-1.31B |
| Common Stock Repurchase | N/A | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | IART | BSX |
|---|---|---|
| Shares Short | 7.19M | 18.99M |
| Short Ratio | 4.79 | 3.17 |
| Short % of Float | 0.15% | 0.01% |
| Average Daily Volume (10 Day) | 1,202,480 | 7,267,900 |
| Average Daily Volume (90 Day) | 1,384,253 | 6,400,743 |
| Shares Outstanding | 77.16M | 1.47B |
| Float Shares | 59.27M | 1.48B |
| % Held by Insiders | 0.14% | 0.00% |
| % Held by Institutions | 0.95% | 0.94% |
Dividend Analysis & Yield Comparison: Integra LifeSciences vs Boston Scientific
| Metric | IART | BSX |
|---|---|---|
| Last 12-Month Dividend | N/A | N/A |
| Last 12-Month Dividend Yield | N/A | N/A |
| 3-Year Avg Annual Dividend | N/A | N/A |
| 3-Year Avg Dividend Yield | N/A | N/A |
| 3-Year Total Dividends | N/A | N/A |
| Ex-Dividend Date | N/A | N/A |